Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT01650805 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.

NCT NCT01650805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01650805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Lead sponsor
Ariad Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2012
Completion date
October 31, 2013
Enrollment
307 (actual)
Sites
170

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia